CTLA4 and neoplasm: Our results showed that high level of PD1, PD-L1 and CTLA4 was observed in TNBC patients with low IRGriskscore, which strongly implicated that TNBC patients with low IRGriskscore might be suitable for anti-tumor immunotherapy.